Development of Medical Countermeasures to Middle East Respiratory Syndrome Coronavirus

Preclinical development of and research on potential Middle East respiratory syndrome coronavirus (MERS-CoV) medical countermeasures remain preliminary; advancements are needed before most countermeasures are ready to be tested in human clinical trials. Research priorities include standardization of...

Full description

Saved in:
Bibliographic Details
Published in:Emerging infectious diseases 2016-07, Vol.22 (7)
Main Authors: Uyeki, Timothy M, Erlandson, Karl J, Korch, George, O'Hara, Michael, Wathen, Michael, Hu-Primmer, Jean, Hojvat, Sally, Stemmy, Erik J, Donabedian, Armen
Format: Article
Language:English
Subjects:
animal models
Animals
Camelus
Coronavirus Infections - prevention & control
Coronavirus Infections - veterinary
Coronavirus Infections - virology
Development of Medical Countermeasures to Middle East Respiratory Syndrome Coronavirus
Disease Models, Animal
Humans
medical countermeasures
MERS-CoV
Middle East Respiratory Syndrome Coronavirus
NHPs
non-human primates
Online Report
Viral Vaccines - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Preclinical development of and research on potential Middle East respiratory syndrome coronavirus (MERS-CoV) medical countermeasures remain preliminary; advancements are needed before most countermeasures are ready to be tested in human clinical trials. Research priorities include standardization of animal models and virus stocks for studying disease pathogenesis and efficacy of medical countermeasures; development of MERS-CoV diagnostics; improved access to nonhuman primates to support preclinical research; studies to better understand and control MERS-CoV disease, including vaccination studies in camels; and development of a standardized clinical trial protocol. Partnering with clinical trial networks in affected countries to evaluate safety and efficacy of investigational therapeutics will strengthen efforts to identify successful medical countermeasures.
ISSN:1080-6040
1080-6059
DOI:10.3201/eid2207.160022